EB-NK-MF (MSLN/FRalpha)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameEB-NK-MF (MSLN/FRalpha)
Drug Alias NameEB-NK-MFEB-MF-CAR-NK-01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsMesothelin modulatorsFolate receptor alpha modulators
TargetsMesothelinFolate receptor alpha
Therapy Area/IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A